We did not use the Akt inhibitors like GSK 690693 to confirm the PRAME overexpression-induced malignant behavior in the LSCC cell lines and primary tumor xenografts, contributing to enhance our hypothesis that PI3K/AKT/mTOR is involved in LSCC development. The gene discussed is AKT1; the disease is neoplasm.